Core Viewpoint - The company BoHui Innovation (300318) announced that its subsidiary BoHui Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for a freeze-dried rabies vaccine using human diploid cells [1] Group 1 - BoHui Biopharmaceutical Co., Ltd. is collaborating with Beijing Baihui Biotechnology Co., Ltd. for the rabies vaccine project [1] - The approval includes a formal notification for the initiation of clinical trials [1]

Core Viewpoint - The announcement indicates that the company’s subsidiary, Bohui Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for a lyophilized rabies vaccine, which is intended to stimulate immune response against rabies [1] Group 1: Company Developments - Bohui Innovation announced that its subsidiary has jointly applied for a rabies vaccine with Beijing Baihui Biotechnology Co., Ltd. [1] - The rabies vaccine is designed to prevent rabies by using purified rabies virus antigens to stimulate the immune response [1] - The approval for clinical trials is a significant step in the vaccine development process, although the company notes that drug development involves high investment, high risk, and long cycles [1] Group 2: Market Context - Currently, the domestic market for human rabies vaccines includes manufacturers such as Chengdu Kanghua Biological Products Co., Ltd. and Beijing Minhui Biotechnology Co., Ltd. [1] - The company acknowledges potential risks associated with drug development, including clinical trial outcomes not meeting expectations and delays in regulatory approvals or market entry [1] - The approval for the clinical trial is not expected to have a significant impact on the company's short-term performance [1]

每经讯，2026年1月13日，北交所上市公司康乐卫士（920575，收盘价：11.99元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日收盘价涨幅达到29.90%，成交数量3511.98万股，成交金额4.02亿元。买一席位为甬兴证券有限公司宁波和源路证券营业 部，买入1768.5万元；卖一席位为国金证券股份有限公司成都武成大街证券营业部，卖出2759.29万元。 | | 2026-01-13康乐卫士 (920575) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | न्द्र ग | 用兴证券有限公司宁波和源路证券营业部 | 17684998.21 | 0 | | 址2 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 10787525 | 11314658.06 | | ग्रें3 | 东方证券股份有限公司昆明白龙路证券营业部 | 9962715.23 | 0 | | 买4 | 东吴证券股份有限公司苏州相城采莲路证券营业部 | 8461071.27 | 0 | | ન્નેર | 华安证券股份有 ...

Core Viewpoint - The company, Fuhong Hanlin (02696.HK), has announced that its self-developed Hanbeitai® (Bevacizumab Injection) has had its biological product license application accepted by the U.S. Food and Drug Administration (FDA) [1] Group 1: Product and Indications - The application involves several indications, including: 1. Metastatic colorectal cancer 2. First-line treatment of unresectable locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel 3. Recurrent adult glioblastoma 4. Treatment of metastatic renal cell carcinoma in combination with interferon α 5. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 6. Treatment of persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan [1]

Core Viewpoint - The news highlights the strong performance of WuXi AppTec, with significant revenue and profit growth projections for 2025, driven by its integrated CRDMO business model and increasing demand for its services [3][4]. Group 1: Company Performance - WuXi AppTec expects to achieve approximately 454.56 billion yuan in revenue for 2025, representing a year-on-year growth of about 15.84%, with a 21.4% increase in revenue from continuing operations [3]. - The adjusted net profit attributable to shareholders is projected to be around 149.57 billion yuan, reflecting a year-on-year increase of approximately 41.33% [3]. - The company has revised its revenue guidance upwards, with total revenue expectations adjusted from 425-435 billion yuan to 435-440 billion yuan for 2025 [3]. Group 2: Market Trends - The Hang Seng Biotechnology ETF (513280) saw a 1.57% increase, with trading volume exceeding 1.4 billion yuan, indicating a significant uptick in market interest [1]. - WuXi AppTec's stock rose over 8%, outperforming many peers in the biotechnology sector, which also saw positive movements [4]. Group 3: Industry Insights - The AI healthcare application sector is rapidly advancing, with significant policy support and market demand driving commercialization [6]. - AI in drug development is expected to enhance early-stage research efficiency, significantly reducing the time required for drug candidate identification [6][7]. - The integration of AI in healthcare is becoming increasingly prevalent, with tools like ChatGPT Health facilitating better health information management for users [8][9].

智飞生物于2026年1月5日晚间发布关于公司控股股东部分股份解除质押的公告称，公司近日接到公司控 股股东、实际控制人蒋仁生的通知，获悉蒋仁生所持有公司的部分股份解除质押。 蒋仁生本次解除质押股数为65,450,000股，占其所持股份比例5.64%，占智飞生物总股本比例2.73%，解 除日期为2025年12月30日，质权人为重庆农村商业银行股份有限公司。 截至公告披露日，蒋仁生持股数量1,159,573,500股，持股比例为48.44%，累计被质押股份数量为 119,250,000股，合计占其所持股份比例10.28%，合计占智飞生物总股本比例4.98%。 中国经济网北京1月13日讯智飞生物（300122）(300122.SZ)昨日晚间发布2025年度业绩预告。 智飞生物预计2025年度归属于上市公司股东的净亏损为1,069,793.61万元至1,372,565.38万元，比上年同 期下降630%至780%；预计2025年度扣除非经常性损益后的净亏损为1,055,434.85万元至1,354,142.82万 元，比上年同期下降630%至780%。 2024年，智飞生物实现营业收入260.70亿元，同比下降50.7 ...

Core Viewpoint - The company, Fuhong Hanlin (02696), has announced that its self-developed Hanbeitai (Bevacizumab Injection) has had its Biologics License Application (BLA) accepted by the U.S. Food and Drug Administration (FDA) [1] Group 1: Product Approval - The BLA acceptance involves multiple indications, including metastatic colorectal cancer [1] - It also includes first-line treatment for unresectable locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel [1] - Other indications include recurrent adult glioblastoma, metastatic renal cell carcinoma in combination with interferon α, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, and persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan [1]

Core Viewpoint - The company, Fuhong Hanlin (02696), has announced that its self-developed Hanbeitai® (Bevacizumab Injection) has received acceptance for its Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) [1] Summary by Categories Product Development - The BLA application for Hanbeitai® includes indications for: 1. Metastatic colorectal cancer 2. First-line treatment of unresectable locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel 3. Recurrent adult glioblastoma 4. Treatment of metastatic renal cell carcinoma in combination with interferon α 5. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 6. Treatment of persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan [1]

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received acceptance from the FDA for its Biologics License Application (BLA) for Hanbeitai® (Bevacizumab Injection), indicating a significant step forward in its drug development pipeline [1] Group 1: FDA Acceptance - The FDA has accepted the BLA for Hanbeitai®, which is a major milestone for the company [1] - The application includes multiple indications, showcasing the drug's potential versatility in treating various cancers [1] Group 2: Indications Included - The BLA covers the following indications: 1. Metastatic colorectal cancer 2. First-line treatment of unresectable locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer in combination with Carboplatin and Paclitaxel 3. Recurrent adult glioblastoma 4. Metastatic renal cell carcinoma in combination with Interferon α 5. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 6. Persistent, recurrent, or metastatic cervical cancer in combination with Paclitaxel and Cisplatin, or Paclitaxel and Topotecan [1]

Core Viewpoint - UBS report indicates that Innovent Biologics is confident in its sales performance in the Chinese market, driven by oncology and cardiovascular products, and aims to achieve a product sales target of 20 billion yuan by 2027 [1] Group 1 - Innovent Biologics is focusing on the sales performance of its products in the Chinese market and the development progress of the key candidate drug IBI363 (PD-1/IL-2a) in collaboration with Takeda Pharmaceutical [1] - The company maintains its target of achieving 20 billion yuan in product sales by 2027 [1] - Innovent aims to advance five candidate drugs into global multi-center randomized controlled trial stages before 2030 [1] Group 2 - UBS sets a target price of HKD 137.4 for Innovent Biologics and maintains a "Buy" rating [1]